Nuvation sets its sights on Voranigo
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
Ono takes on Takeda in polycythemia vera
The Japanese group licenses sapablursen from Ionis for $280m.
No lost causes at Xilio and Lyell
The companies press on with vilastobart and IMPT-314... up to a point.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Private biotechs and novel targets head for human trials
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
Son of Darzalex hits the skids
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
